Effects of Letrozole And Metformin Versus Metformin alone on incretin in Iraqi patients with PCOS

Authors

  • Dr. Shatha Salih Mahdi B.Sc. Pharmacy/ Alyarmok University college ( 2013 )
  • Dr. Sinaa Abdul Amir Kadhim MBChB, MSc, PhD. Professor in Pharmacology, College of Medicine, University of Al-Qadisiyah. Iraq

DOI:

https://doi.org/10.70135/seejph.vi.1127

Keywords:

incretin, PCOS, letrozole, metformin

Abstract

I Background: The emergence of numerous novel therapeutic agents for managing T2DM has expanded the assortment of tailored therapies available for PCOS sick. One illustration of these is the incretin-based therapeutic agents.

Patients and methods:The extanttrainingcomprised 75 sickthrough an age extent of 18 to less than 40 years. Patients were categorized into three groups: metformin group (positive control group) and they received metformin as 500 mg per-oral (bid); letrozole group who were treated using 2.5 mg per-oral (bid), and combination groups who received both agents with similar doses as above. Each group included 25 females. Informationalmost age and body mass index (BMI) stayed included in the study. Serum measurement of incretin (GLP-1) was done before treatment and 90 days after treatment using Enzyme-Linked Immunosorbent Assay.

Results: There stayed no importantvariance in mean age (p = 0.981) betweentraining groups and  means of age were 29.24 ± 6.10 years, 29.56 ± 5.50 years and 29.44± 5.83 years, respectively and the range of age was between 18 and 40 years. In addition, in this training, there stayed no importantalteration in mean BMI (p = 0.534) among study groups and means of BMI were 28.80 ±2.72 kg/m2, 27.53 ±1.95 kg/m2 and 27.07 ±1.99 kg/m2, respectively and the range of BMI was between 21.07 and 31.18  kg/m2. Serum incretin (GLP-1) level showed no significant variation among study groups, the mean levels were in the range of 10.87 -13.79 ng/ml and the range of values was from 9.56 -14.49 ng/ml. Changes in BMI are shown in. Metformin alone caused in more important weight decrease; nevertheless, adding of letrozole caused significant reduction in body mass index, letrozole alone also affect body weight significantly. It was observed that combined use of either drug resulted in more significant change of GLP-1 level at (p ≤ 0.001).

Conclusion: Combined treatment with letrozole and metformin is safe and efficient in femalesby PCOS resultant in weight decrease, improved insulin

Downloads

Published

2024-09-30

How to Cite

Mahdi, D. S. S., & Kadhim, D. S. A. A. (2024). Effects of Letrozole And Metformin Versus Metformin alone on incretin in Iraqi patients with PCOS. South Eastern European Journal of Public Health, 239–244. https://doi.org/10.70135/seejph.vi.1127

Issue

Section

Articles